|
|
nAMD and DME: Novel Treatment Plans to Prioritize Real-World Visual Improvements
Frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapies can significantly improve visual and anatomical outcomes for many patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, the requisite high number of treatments often leads to less-than-ideal results compared to outcomes reported in major clinical trials, largely due to the demanding treatment schedule. Adopting tailored treatment plans, along with ... |
|
|
Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are increasingly prevalent retinal diseases that pose significant challenges in ophthalmic care. While anti-vascular endothelial growth factor (VEGF) therapies have greatly improved visual outcomes for patients with these conditions, real-world data indicate that many patients receive suboptimal treatment and monitoring, resulting in poorer visual outcomes. Newer therapeutic options have been developed to exte... |
|
|
Nutraceuticals for Dry Eye: Dispelling the Dogma and Embracing the Data
Dry eye disease is a common yet frequently overlooked condition that significantly affects quality of life. Despite an estimated global prevalence of up to 50%, DED is often underdiagnosed and inadequately managed. To limit the burden of DED, it is crucial for clinicians to be adept at recognizing risk factors and making accurate diagnoses. In addition, as treatment options expand to include clinically proven nutraceuticals, it is imperative that clinicians stay abreast of the latest clinical ... |
|
|
Patient‐Centered GA Care: A Synergistic Approach to Optimize Management
The recent FDA approval of 2 novel therapies for the management of patients with geographic atrophy (GA) secondary to age-related macular degeneration has further reenforced the necessity for early GA diagnosis to limit progression. Advances in imaging technologies now provide tools for better detection and characterization of GA, along with biomarkers to monitor progression over time. Optometrists, as front-line eye healthcare providers, play a critical role in the timely diagnosis, managemen... |
|
|
The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like under-treatment and patient non-adherence. New and emerging therapies, particularly for conditions like diabetic macular edema (DME), diabetic retinopathy, and geographic atrophy (GA) secondary to... |
|
|
nAMD, Diabetic Eye Disease, and RVO: State-of-the-Art Management
The continued evolution of diagnostic, therapeutic, and surgical algorithms for the management of patients with retinal diseases offer the potential for enhancing visual, anatomical, and quality-of-life outcomes in these patients. Recognition, understanding, and application of these evidence-based advances are imperative to enhance treatment outcomes and patient satisfaction. During Part 1 of this 2-part educational activity, updates in state-of-the-art management strategies for neovascular ag... |
|